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OBJECTIVE: We aimed to estimate the overall survival (OS) and conditional survival (CS) in patients diagnosed
with oral and oropharyngeal squamous cell carcinoma (SCC) and to determine their survival trends.
METHODS: The study included all consecutive patients treated at the A.C. Camargo Cancer Center for oral or
oropharyngeal SCC between 2001 and 2012. Data were obtained from the Hospital Cancer Registry. OS and CS
were analyzed using the Kaplan-Meier method to evaluate the probability of survival with Cox predictor
models.
RESULTS: Data of 505 oral and 380 oropharyngeal SCC patients obtained in 2001–2006 and 2007–2012 were
analyzed. Most of the oral SCC (59%) and oropharyngeal SCC (90%) patients had stages III–IV SCC. The 5-year OS
for patients with oral SCC was 51.7%, with no significant difference between the first and second periods. The
CS rates in 2007–2012 were 65% after the first year and 86% up to the fifth year. For oropharyngeal SCC, the
5-year OS rate was 45.0% in the first period. The survival rate increased to 49.1% from 2007 to 2012, with a
reduction in the risk of death (HR=0.69;0.52–09.2). The CS estimates from 2007 to 2012 were 59% after the first
year and 75% up to the fifth year.
CONCLUSION: Survival across the two time periods remained stable for oral SCC but showed a significant
increase for oropharyngeal SCC, possibly because of improvements in the patients’ response to radiotherapy,
such as intensity-modulated radiation therapy, and the use of more accurate diagnostic imaging approaches.
KEYWORDS: Survival Analysis; Prognosis; Oral Cavity; Oropharynx; Cancer.
’ INTRODUCTION
In 2018, 354,864 new cases of lip and oral cancer (OC) and
92,877 new cases of oropharyngeal cancer were reported
worldwide. The number of deaths from lip cancer and OC
was 51,005, whereas that from oropharyngeal cancer was
51,005 (1). In 2018, 19,898 new cases of lip cancer and OC
were reported in Latin America and Caribbean countries (1),
whereas 14,700 new cases were reported in Brazil (2). A total
of 9,180 individuals from Latin America and Caribbean
countries and 4,629 from Brazil developed oropharyngeal
cancer (1). Therefore, the number of individuals diagnosed
with oral and oropharyngeal squamous cell carcinoma (SCC)
in Brazil is almost half the number of those diagnosed with
oral and oropharyngeal SCC in Latin America and Carib-
bean countries.
Cancers in the oral cavity and oropharynx are classified as
head and neck cancers, and 90% of them are SCC (3,4).
Tobacco and alcohol use are the main risk factors for OC. For
oropharyngeal cancer, human papilloma virus (HPV) infec-
tion has also been considered a risk factor and prognostic
biomarker (5-7).
The survival rates for head and neck cancer vary
depending on the site involved (7). Previous European and
American population-based studies reported that the 5-year
relative survival of German people with OC diagnosed
in 2002–2006 was 54.6% (8), whereas that of Danish people
with head and neck cancer was 62.4% (2010–2014) (9). For
American individuals with cancer in the oral cavity, oro-
pharynx, and subsites (base of tongue, hard palate, tonsil,
etc.), SEER reported a 5-year relative survival of 62.9% (4).
In the United States (US), the 5-year relative survival
of oropharyngeal cancer patients increased from 33.3% in
1992–1996 to 42.2% in 2002–2006 (4).DOI: 10.6061/clinics/2020/e1507
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On the basis of the hospital data, there were differences in
overall survival (OS) rates between public and private
institutions. In Argentina, the survival estimate for OC was
39% in public hospitals (10). In Chile, the survival estimate
for OC was 46% in private hospitals (11). In Brazil, Santa
Catarina reported a 5-year OS for OC and pharyngeal cancer
of 33.3% (12). In Maceio, northeast of Brazil, the 5-year OS for
oropharyngeal cancer was 27.8% (12,13). In Santa Maria,
south of Brazil, the 5-year OS for OC and oropharyngeal
cancer was 42%; however, patients with oropharyngeal
cancer had the worst survival rates (14).
Retrospective studies have shown survival differences
according to tumor site and subsite (base of tongue, hard
palate, and tonsil) for oropharyngeal cancer and sex and age
for OC (15).
Conditional survival (CS) provides an estimate of the
chances of surviving in the second to the fifth year after
diagnosis, after surviving for at least a year; it is a dynamic
survival indicator wherein the prognosis is based on the
number of years survived after treatment (16,17). Thus, we
evaluated the survival of patients with OC and orophar-
yngeal cancer by assessing their OS and CS rates in order to
provide prognostic information. CS analysis provide prog-
nostic information for cancer survivors; it was performed to
estimate the probability of survival after 1 to 5 years (17). In
the US, a marked improvement in the CS of oropharyngeal
cancer patients (26.6%–60.0%) was observed during the
period 1997–1998 (18).
The present study aimed to estimate the OS and CS in
patients diagnosed with oral and oropharyngeal SCC at the
A.C. Camargo Cancer Center (ACCCC) in Sao Paulo, Brazil,
to determine the progress in patients’ survival. The study
was conducted in H&N patients treated at a specialized
treatment center between 2001 and 2012.
’ METHODS
Data of patients diagnosed with oral SCC (C02, C05 except
C051-C052, and C06) and oropharyngeal SCC (C01, C051-
C052, C09, and C10) according ICD-O3 between 2001 and
2012 were extracted from the Hospital Cancer Registry of
ACCCC (19); the morphological codes (8050/3, 8070/3,
8074/3, 8076/3, and 8083/3) (19) for oral and oropharyngeal
SCC were registered at the ACCCC with follow-up until
December 31, 2017. The Ethics Committee approved the
study (no 2462/17 on Dec 5, 2017). The patients were
stratified by age group (p50 years, 51–60 years, and 460
years); sex (male and female), diagnostic period (2001–2006
and 2007–2012), clinical stage (I–II and III–IV) (20,21) and
treatment procedure (surgery alone, surgery with chemor-
adiation, and other/palliative care). The absolute and
relative frequencies were described.
OS was calculated from the date of diagnosis to the date
of death (of any cause) or the date on which the latest
information was available. Survival curves were calculated
using the Kaplan-Meier method; the probabilities for sur-
vival at 1 year, 3 years, and 5 years were described using
independent variables. The differences in survival curves
were compared using a log-rank test. The hazard ratio (HR)
as its corresponding 95% confidence interval (CI) were
determined using a Cox regression model.
We calculated the CS, which is the dynamic probability of
the patient surviving t years, given that a patient has already
survived for s years after diagnosis (22). Thus, we were able
to estimate the patient’s chance of surviving an additional
t years after surviving for s years (with the total being
t+s years). CS was calculated on the basis of survival pro-
bability data accumulated using the Kaplan-Meier method
according to the following formula:
CS¼ SðtjsÞ¼ Sðtþ sÞ
SðsÞ
CS rates were plotted for 1–5 years after diagnosis. The
level of significance was 5% for all hypotheses. All analyses
were performed using SPSS v.25 for Windows.
’ RESULTS
Between 2001 and 2012, 885 patients with oral and
oropharyngeal SCC were treated at ACCCC. Of them, 505
had OC, whereas 380 had oropharyngeal cancer. In rela-
tion to age distribution, 50% of patients with OC were aged
460 years, whereas 42% of those with oropharyngeal cancer
were aged. With regard to sex, OC (2:1) and oropharyngeal
cancer (6:1) were more common in men. The majority of
patients had advanced-stage (stage III–IV) cancer (OC: 59%
(290/505), oropharyngeal cancer: 90% (339/380); Table 1). The
proportions of patients with missing 5-year clinical follow-up
data were 6.4% (OC) and 3.9% (oropharyngeal cancer).
Oral SCC
There was an improvement in the treatment (combining
surgery and chemoradiotherapy) response of stage III–IV
patients, which increased from 48.7% in 2001–2006 to 63.2%
in 2007–2012 (po0.006) (Table 2).
The OS rates for OC were 79.0%, 58.4%, and 51.7% in the
first, third, and fifth years after diagnosis, respectively. The
OS for oral SCC in 2001–2006 was 49.7% and that in 2007–
2012 was 53.1% (p=0.440) (Figure 1a). The 5-year OS was
higher in patients aged p50 years (61.8%) and in those with
stage I–II cancer (74.0%) (Table 3). The risk of death was 1.42
times higher in patients with oral SCC aged 460 years and
3.58 higher in those with clinical stage III–IV SCC (Table 4).
CS of patients with oral SCC increased from 65% after the
first year to 86% in the fifth year after diagnosis, demonstrat-
ing an improvement in survival in the most recent period
Table 1 - Characteristics of patients with oral and oropharyngeal
SCC treated at the A.C. Camargo Cancer Center during the
diagnostic period, HCR, 2001–2012.
Oral cavity Oropharynx Total
N=505 N=380 N=885
Characteristics n (%) n (%) n (%)
Age group (yrs)
p50 118 (23.4) 82 (21.6) 200 (22.6)
51–60 139 (27.5) 138 (36.3) 277 (31.3)
460 248 (49.1) 160 (42.1) 408 (46.1)
Gender
Male 335 (66.3) 324 (85.3) 659 (74.5)
Female 170 (33.7) 56 (14.7) 226 (25.5)
Period of diagnosis
2001–2006 197 (39.0) 129 (33.9) 326 (36.8)
2007–2012 308 (61.0) 251 (66.1) 559 (63.2)
Clinical stage
I–II 203 (41.2) 37 (9.8) 240 (27.6)
III–IV 290 (58.8) 339 (90.2) 629 (72.4)
SCC, squamous cell carcinoma; HCR, Hospital Cancer Registry.
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(Figure 2b). With the passage of time, the chances of survival
increase. However, the risk of death from oral SCC remained
unchanged in the two study periods.
Oropharyngeal SCC
Approximately 75.7% of patients with oropharyngeal SCC
were treated with chemoradiation, with differences noted
between the first and second period (po0.001). Of the
patients with stage III–IV cancer treated between 2001 and
2006, 31% received chemoradiation; between 2007 and 2012,
71.7% of the patients received chemoradiation (Table 2). OS
probabilities for oropharyngeal SCC were 76.3% and 45.0%
in the first and fifth years after diagnosis, respectively. The
5-year OS was higher in patients diagnosed between 2007
and 2012 (49.1%; p=0.010) (Figure 1b), those agedp50 years
(58.1%; p=0.007), and those with stage I–II cancer (75.2%;
po0.001) (Table 3). The HR in the adjusted analysis and risk
of death were higher in patients aged 460 years (HR 1.88)
and those with stage III–IV disease (HR: 3.23) (Table 4).
The 5-year CS after having survived for 1 year was 48% for
those diagnosed between 2001 and 2006 and 59% for those
diagnosed between 2007 and 2012 (Figure 2b). Therefore, the
survival rate of oropharyngeal SCC increased in the more
recent period.
’ DISCUSSION
The 5-year OS rates were 52% for oral SCC and 45% for
oropharyngeal cancer in the period 2001–2012. However,
the 5-year survival of patients with oral SCC remained
unchanged (49.7%–53.1%), whereas that of patients with
oropharyngeal SCC increased from 37.2% to 49.1%. By
contrast, Ridder et al. reported a 5-year survival rate of 60%
(15), whereas Du et al. (23) reported 5-year survival rates of
69% and 56% for OC and oropharyngeal cancer, respectively.
The majority of patients with oral SCC in our study were
aged 60 years, whereas those with oropharyngeal SCC
tended to be younger, which is similar to the findings in
the literature (24). A previous study conducted in ACCCC
identified that comorbidities are prognostic factors for older
adults with head and neck cancer (25). A review by Vander
Wale et al. (26) described that the treatment toxicity can be
quite morbid for older adults as they are often excluded from
clinical trials that provide definitions on the standards of care.
In both OC and oropharyngeal cancer, we observed an
increase in mortality risk for patients aged 460 years and
those with stage III/IV SCC, which is similar to the findings
reported by Ridder et al. (15). Although a greater mortality
risk was reported in men (15,21,23,24), this study did not
find a survival difference between sexes.
The 5-year OS for stage I–II patients with OC and oro-
pharyngeal cancer was around 74%, although the proportion
of patients with early-stage (I–II) OC was 41% and that of
patients with early-stage (I–II) oropharyngeal cancer was
9.8%. Zanoni et al. (27) reported an OS rate of 64.4% (1985–
2015) for OC patients admitted at the Memorial Sloan
Kettering Cancer Center, a rate higher than that observed in
this study; however, 58% of the patients treated had stage
I–II SCC, whereas 39% had stage III–IV SCC. In 11 hospitals
in Europe, 45% of the OC patients had stage III–IV SCC (15).
Table 2 - Treatment adopted for patients with oral and oropharyngeal squamous cell carcinoma at the A.C. Camargo Cancer Center,
according to period of diagnosis and clinical stage, HCR, 2001–2012.
Period of diagnosis
Clinical stage Treatment 2001–2006 2007–2012 Total p
Oral cavity
I-II Surgery only 60 (80) 100 (78.1) 160 (78.8) 0.494
Surgery with (C)RT 13 (17.3) 24 (18.8) 37 (18.2)
(C)RT 1 (1.3) 4 (3.1) 5 (2.5)
Palliative 1 (1.3) 0 (0) 1 (0.5)
Subtotal 75 (100) 128 (100) 203 (100)
III-IV Surgery only 45 (37.8) 34 (19.9) 79 (27.2) 0.006
Surgery with (C)RT 58 (48.7) 108 (63.2) 166 (57.2)
(C)RT 11 (9.2) 24 (14) 35 (12.1)
Palliative 5 (4.2) 5 (2.9) 10 (3.4)
Subtotal 119 (100) 171 (100) 290 (100)
Total Surgery only 107 (54.3) 139 (45.1) 246 (48.7) 0.087
Surgery with (C)RT 71 (36) 134 (43.5) 205 (40.6)
(C)RT 12 (6.1) 29 (9.4) 41 (8.1)
Palliative 7 (3.6) 6 (1.9) 13 (2.6)
Total 197 (100) 308 (100) 505 (100)
Oropharynx
I-II Surgery with or without (C)RT 10 (83.3) 18 (72.0) 28 (75.7) 0.452
(C)RT 2 (16.7) 7 (28.0) 9 (24.3)
Subtotal 12 (100) 25 (100.0) 37 (100.0)
III-IV Surgery with or without (C)RT 71 (61.2) 57 (25.6) 128 (37.8) o0.001
(C)RT 36 (31.0) 160 (71.7) 196 (57.8)
Palliative 9 (7.8) 6 (2.7) 15 (4.4)
Subtotal 116 (100.0) 223 (100.0) 339 (100.0)
Total Surgery with or without (C)RT 81 (62.8) 77 (30.7) 158 (41.6) o0.001
(C)RT 39 (30.2) 167 (66.5) 206 (54.2)
Palliative 9 (7.0) 7 (2.8) 16 (4.2)
Total 129 (100.0) 251 (100.0) 380 (100.0)
(C)RT, (chemo)radiotherapy; HCR, Hospital Cancer Registry.
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Du et al. (23) observed that 38% of OC patients had stage III–
IV SCC, whereas 59% had stage III–IV SCC. Amit et al. (28),
in a multicentric international study conducted in seven
international institutions including ACCCC in two decades
(1990 to 2011), reported an improvement (from 59% to 70%)
in the survival of patients with OC in the most recent period.
The multicenter CHANCE study (USA) reported a 54%
5-year OS for OC (21), which is similar to our data. In
Portugal, Monteiro et al. (29) observed that 71% of their
patients with OC were diagnosed at stage III–IV, with a
survival rate of 41%, without significant improvements over
time (38% for 2000–2004 and 42% for 2005–2009). In a
university hospital in Santa Maria, Brazil, the OS was 42% in
2004–2014 (14). Thus, the OS rate for patients with OC has
been around 55% at most treatment centers.
Survival for oropharyngeal cancer improved significantly
between 2001 and 2012 (from 37.2% to 49.1%), although
around 90% of the treated patients had stage III–IV cancers.
The presence of HPV in the oropharynx and its role as a
prognostic factor affected the therapeutic planning in these
cases and had an influence on the improvement in survival
(5). Brazilian studies showed that the majority of patients
diagnosed with oropharyngeal cancer are not HPV-positive
(i.e., low prevalence, 3%–9%) (30,31).
Figure 1 - Overall survival of patients with oral and oropharyngeal squamous cell carcinoma treated at the A. C. Camargo Cancer
Center, Hospital Cancer Registry, 2001–2012, by period of diagnosis.
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A review on the treatment of older patients with head and
neck cancer indicated that oropharyngeal cancer patients
aged 65 years and older have survival outcomes similar to
those of younger patients with head and neck cancer;
however, they may experience worse toxicity (26). Sandu-
lache et al. (32) reported a 40% 5-year OS for oropharyngeal
cancer and indicated that 30% of the patients were unable to
complete the treatment.
For locally advanced oropharyngeal cancer, chemotherapy
combined with radiation treatment has been reported to
significantly improve OS (33,34). Du et al. (23) observed that
84% of oropharyngeal cancer patients had stage III–IV
cancers, which is the same as the finding of this study
(90%). Monteiro et al. (29) reported a 27% 5-year OS rate
for oropharyngeal cancer, with a significant reduction in
mortality from 2000–2004 (28%) to 2005–2009 (24%) in
Northern Portugal. Patients with advanced stages have
worst survival (35). Although 90% of the patients with
oropharyngeal cancer treated at the ACCCC had clinical
stage III–IV cancers, the survival among these patients
increased from the previous period to the more current
period, likely because of the changes in therapeutic planning,
such as the use of IMRT and new target therapies (36).
For oropharyngeal cancer, there was a difference in terms
of the period of diagnosis, with a lower risk of death
observed in patients treated in the more recent period (2007–
2012), similar to the findings of Monteiro et al. (29).
With regard to the 5-year CS of OC patients, CS increased
to 17% in patients who survived 1 year and to 13% in those
who survived 5 years after the diagnosis (2007–2012 versus
2001–2006); similar results were observed in a single insti-
tution in the same period (37).
For oropharyngeal cancer, a similar increase in CS was
observed in 2007–2012 and 2001-2006; the probability of CS
Figure 2 - Five-year probability conditional survival of patients with oral and oropharyngeal squamous cell carcinoma treated at the
A. C. Camargo Cancer Center, Hospital Cancer Registry 2001–2012, according period of diagnosis. Oro, oropharynx; OC, oral cavity.
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at the first year was 11%, and it increased to 14% after
5 years. The CS of oral cancer patients 5 years after diagnosis
had increased, whereas that of patients with oropharyngeal
cancer had decreased. The decrease in oropharyngeal cancer
survival after 5 years remains unclear.
The lack of progress in CS among older adults with oral
and oropharyngeal SCC could be related to the presence of
comorbidities and other competitive causes of death. In this
article, because of the number of patients, we were not able
to stratify patients by age, stage, and period to estimate the
CS as Yang et al. (17) described.
The OS of patients with OC and oropharyngeal cancer
increased from 2007 to 2012; however, the majority of
patients who underwent treatment had advanced-stage
cancer. The OS of patients with stage I and II oral SCC was
74%, whereas that of oropharyngeal SCC patients was 75.2%,
which is two times higher than the rates observed among
those with stage III and IV cancers with these topographies.
Hospital Cancer Registries are database that were created
under the law (38) in Brazil, but the use of these registries has
limitations: they cannot provide comprehensive clinical infor-
mation and data on patients’ outcomes. At ACCCC, the
Hospital Cancer Registry is in collaboration with Fundac¸ão
Oncocentro de São Paulo; from 2000 to 2012, the registry had
36,343 registered cancer cases (39).
The limitation of this study is the lack of information on
the p16 status for oropharyngeal SCC because this biomarker
had not yet been routinely adopted during the study period
and the cause of death was not described in the Hospital
Cancer Registry.
Therefore, early diagnosis of OC and oropharyngeal
cancer is likely to increase the chances of cure and survival
among these patients.
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